This insight was an incentive for the initiation of a study that would explain the possible involvement of well-known BC prognostic markers, such as p53 protein expression, FGFR3 expression, and its gene mutations status, in the prediction of tumor response to specific anti-PD-L1 therapy. This evidence concerns the gene FGFR3 and neoplasm.